Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam
Mohamad Yasmin, Jennifer Hanrahan, Steven Marshall, Thomas P. Lodise, Liang Chen, Federico Pérez, Barry N. Kreiswirth, Robert A. Bonomo
Abstract
Abstract This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)–3–producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC–Klebsiella pneumoniae central nervous system infections.
Topics & Concepts
Klebsiella pneumoniaeMedicineCeftazidime/avibactamCeftazidimeBacteremiaMeningitisCerebrospinal fluidMicrobiologyAntibioticsInternal medicinePseudomonas aeruginosaSurgeryBiologyBacteriaEscherichia coliGeneGeneticsBiochemistryAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory Infections